Dr. Jean-Paul Kress, M.D.
I Board Chairperson
As the former CEO of MorphoSys, Kress has been instrumental in two significant transactions: the acquisition of Constellation Pharmaceuticals in 2021 and the acquisition of MorphoSys by Novartis in 2024.
Before joining MorphoSys, Kress served as CEO of Syntimmune, where he sharpened the company’s focus on late-stage clinical development, leading to its acquisition by Alexion.
He has also held senior leadership roles at Biogen, Sanofi, Gilead, and AbbVie. Additionally, Kress was Chair of the Board at ERYTECH Pharma, overseeing its merger with Pherecydes, and served as a Board member at Sarepta Therapeutics.
Jean-Paul Kress earned his MD from Faculté Necker-Enfants Malades in Paris and holds advanced degrees in biochemistry and molecular and cellular pharmacology from the École Normale Supérieure.
